• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Pamela Becker Says the US Is "Just Scratching the Surface" for Biosimilars

Video

Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.

Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.

Transcript (slightly modified)

Do you foresee a smoother transition for the biosimilar market in the US going forward?

I think that since there has now been precedence now that the biosimilar pathway to approval has been tested and successfully implemented, I think that will enable other drugs to achieve approval via the biosimilar pathway.

I think we're only just scratching the surface. I think there will be many more biosimilars coming into the marketplace and hopefully the cost reduction that was perceived and part of the motivation for developing the biosimilar approval process, hopefully, those cost savings will be realized for healthcare.

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
dr monica li
dr lawrence eichenfield
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Ross Margulies, health care attorney and partner at Foley Hoag LLP.
dr robert sidbury
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.